Compare Hasbro, Inc. (HAS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Hasbro, Inc. trades at $96.2 (market cap $13.53B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Hasbro, Inc. is far larger — about 2.8× Travere Therapeutics Inc. Common Stock's market cap, and Hasbro, Inc. pays a 2.92% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HAS | TVTX | |
|---|---|---|
Market Cap | $13.53B | $4.88B |
Volume | 1,762,034 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $67.52 |
52-Week Low | $74.13 | $26.79 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $15.72B | $5.01B |
Dividend Yield | 2.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $95.46, up 0.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings beats in recent quarters (Q4 2025-Q2 2026) and positive cash flow trends, though 2025 net income was negative. Valuation metrics include a P/E of 17.07 and P/S of 2.74, while institutional interest remains high with recent purchases by HSBC and Virginia Retirement Systems.
Outlook is positive with a consensus price target of $107.60 (13% upside), supported by Magic: The Gathering growth and cost savings. Risks include high debt levels (debt-to-asset ratio of 59.09% in 2025) and sensitivity to consumer spending trends. The upcoming Q3 2026 earnings on October 20 will be a key catalyst.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
